End-of-day quote
Other stock markets
|
||
- USD | - |
08/07 | CASI Pharmaceuticals Names Daniel Lang CFO | MT |
08/07 | CASI Pharmaceuticals, Inc. Appoints Daniel Lang as CFO | CI |
Sales 2024 * | 19.8M 1.65B | Sales 2025 * | 46.48M 3.89B | Capitalization | 81.64M 6.82B |
---|---|---|---|---|---|
Net income 2024 * | -35M -2.93B | Net income 2025 * | -33M -2.76B | EV / Sales 2024 * | 4.12 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.76 x |
P/E ratio 2024 * |
-2.46
x | P/E ratio 2025 * |
-2.95
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 62.32% |
Managers | Title | Age | Since |
---|---|---|---|
Wei Wu He
CEO | Chief Executive Officer | 59 | 02/19/02 |
Wei Zhang
PSD | President | 64 | 01/18/01 |
Chun Hua Wang
COO | Chief Operating Officer | 52 | 01/17/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Wei Wu He
CEO | Chief Executive Officer | 59 | 02/19/02 |
Yue Wu
BRD | Director/Board Member | 62 | 01/13/01 |
Zhen Bo Su
BRD | Director/Board Member | 48 | 21/23/21 |
1st Jan change | Capi. | |
---|---|---|
+55.35% | 815B | |
+32.04% | 597B | |
-0.10% | 377B | |
+15.47% | 319B | |
+13.10% | 310B | |
+12.80% | 250B | |
+16.30% | 247B | |
+16.54% | 180B | |
+4.31% | 170B |